Jiangsu Trautec
Established in 2015, Trautec is dedicated to the development and production of recombinant collagen based (SRHC) biomaterials for mainly medical and cosmetics industries. SRHC produced by biosynthesis is non-animal produced collagen. As the pioneer of the industry, Trautec operates the full value chain from R&D, manufacturing, to distribution, by holding multiple intellectual property rights in …
Profile
Jiangsu Trautec Medical Technology Co., Ltd. (Trautec), founded in 2015 and headquartered in Changzhou/Jiangsu, develops, manufactures, and sells recombinant collagen-based biomaterials for medical and cosmetic/functional skincare use, operating an end-to-end biosynthesis-to-distribution chain with multiple IP patents. Core offerings/technology include SRHC types I/II/III/XVII (not animal-derived), with standardized large-scale production (e.g., 30-ton fermentation scale) and associated clinical/medical-device transformation capabilities. Shiseido’s fund led an ~RMB 100m strategic investment in 2022, and Trautec later raised RMB 200m Series B in 2023 led by L Catterton (with other investors including CLSA Capital Partners/CITIC CLSA). Reported scale details include a 100,000 sq ft headquarters facility in Jiangsu, >$17m invested in ReCol 3® production, and partnerships with 30 provincial capitals plus 1,000+ hospitals; public English sources don’t disclose revenue/employees. Key partners/customers named include Shiseido, Winona, Proya, Jala, and Sinopharm (plus >30 cosmetic/pharma companies referenced). Latest 2025-2026 developments: the provided sources only list activity through 2021-current and 2024 milestones; they do not confirm 2025-2026 status beyond those items, nor whether the company was still active in 2026. Sources:.
Sources#
- Shiseido Beauty Innovations Fund announces investment in Trautec as lead investor | NEWS RELEASE | Shiseido Company — 2022-08-10
- About
- Trautec Completes RMB 200 Million Series B Fundraise Led by L Catterton — 2023-09-28
- Chinese Collagen Tech Startup Trautec Raises USD27.4 Million — 2023-09-18
- Trautec - Products, Competitors, Financials, Employees, Headquarters Locations — 2023-09-16
- Jiangsu Trautec Medical — Whiteford Research Biobase
- Jiangsu Trautec Medical Technology Co Ltd - Company Profile and News - Bloomberg Markets
- Revolutionizing Skin Repair with Recombinant Type XVII Collagen in China’s Growing Markets
- Industry
- Cosmetics
- Topics
- Hyaluronic acid, collagen & cosmetic bio-actives
- Role
- Producer — “…hangzhou/Jiangsu, develops, manufactures, and sells recombinant collagen-based biomaterials for medical and co…”
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
This company does not publish its products or services — we find out through an introduction.
News & status 6
- 2024-01 Latest status: The company initiated an IPO filing process in January 2024. ↗ ↗ ↗
- Status review: active — Recombinant-collagen implant approved (Dec 2025); A-share IPO preparation.
- 2025-12-23 重磅喜讯 | 创健医疗交联重组胶原蛋白植入剂正式获批_企业动态_新闻中心_江苏创健医疗科技股份有限公司江苏创健医疗科技股份有限公司（Jiangsu Trautec）宣布自主研发的“交联重组胶原蛋白植入剂”已获国家药监局批准上市，成为国内首款同类交联重组胶原蛋白植入剂，适用于面部真皮填充以纠正中重度动力性皱纹（如眉间纹、额头纹、鱼尾纹）。注册证编号为国械注准。
- 2026-03-27 PCHi announces winners of its 2026 Fountain AwardsJiangsu Trautec Medical Technology won a Gold award for their tFNA at the 2026 Fountain Awards. This highlights the company as a leading innovator in anti-wrinkle cosmetic biotechnology recognized by PCHi.
- 2025-07-16 喜讯｜创健医疗入选国家工信部第一批“AI+生物制造”典型案例 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) has been selected by China's Ministry of Industry and Information Technology as part of the first batch of “AI+Biomanufacturing”典型案例, recognizing its AI-assisted design of recombinant collagen as a national benchmark for integrating AI …
- 2025-04-01 喜报 | SCI一区！创健联合珀莱雅共研成果荣登国际权威期刊 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) is highlighted as a leading supplier in recombinant collagen and synthetic biology, collaborating with Jilin University of Technology and Proya to achieve a high-impact, AI-driven study on rhCOL17 published in a top journal, and …
- 2025-05-08 喜讯 | 羟基化率56%！创健医疗获I型、III型重组人胶原蛋白双专利授权_企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) announces a major breakthrough: they have secured dual invention patents for recombinant human collagen types I and III, produced via yeast expression, with a hydroxyproline content of 56%—approaching natural human collagen and promising …
- 2025-01-20 喜讯｜GRAS权威认证！创健医疗重组胶原蛋白获得美国市场准入许可 _企业动态_新闻中心_江苏创健医疗科技股份有限公司Jiangsu Trautec (创健医疗) announces that its recombinant humanized type III collagen has earned GRAS certification, gaining entry to the U.S. market and signaling a major milestone in its global, green, biosynthetic collagen strategy.
Network: owners, partners, peers
Ownership & investors 5
| investor | Shiseido Beauty Innovations Fund |
| investor | L Catterton |
| investor | Boyu Capital |
| investor | CDH Baifu Capital |
| investor | Holley Group Co., Ltd |
Partners & deals 3
| counterparty | Shiseido …The company initiated an IPO filing process in January 2024.… |
| counterparty | L Catterton …The company initiated an IPO filing process in January 2024.… |
| counterparty | CITIC Securities …The company initiated an IPO filing process in January 2024.… |
Similar companies
Sewon Cellontech Co., Ltd. · 山西锦波生物医药股份有限公司 · Shanxi Jinbo bio-pharmaceutical Co., Ltd. · Maxigen Biotech Inc. · Nippi, Inc. · Jland Biotech · Beijing SEMNL Biotechnology Co.,Ltd. · HTL Biotechnology
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member